Mersana Therapeutics Inc (NASDAQ:MRSN) has a beta value of 1.43 and has seen 1.12 million shares traded in the recent trading session. The company, currently valued at $156.99M, closed the recent trade at $1.28 per share which meant it lost -$0.11 on the day or -7.91% during that session. The MRSN stock price is -390.62% off its 52-week high price of $6.28 and 4.69% above the 52-week low of $1.22. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.79 million shares traded. The 3-month trading volume is 1.22 million shares.

The consensus among analysts is that Mersana Therapeutics Inc (MRSN) is Buy stock at the moment, with a recommendation rating of 1.40. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.16.

Mersana Therapeutics Inc (NASDAQ:MRSN) trade information

Sporting -7.91% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the MRSN stock price touched $1.28 or saw a rise of 15.51%. Year-to-date, Mersana Therapeutics Inc shares have moved -10.49%, while the 5-day performance has seen it change -14.67%. Over the past 30 days, the shares of Mersana Therapeutics Inc (NASDAQ:MRSN) have changed -43.61%. Short interest in the company has seen 8.91 million shares shorted with days to cover at 7.58.

Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 57.33% from the levels at last check today. The projected low price target is $3.0 while the price target rests at a high of $3.0. In that case, then, we find that the latest price level in today’s session is -134.38% off the targeted high while a plunge would see the stock gain -134.38% from the levels at last check today.

Mersana Therapeutics Inc (MRSN) estimates and forecasts

Figures show that Mersana Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -31.91% over the past 6 months, with this year growth rate of 58.78%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be -13.81%.

10 analysts offering their estimates for the company have set an average revenue estimate of 7.64M for the current quarter. 5 have an estimated revenue figure of 5.9M for the next ending quarter. Year-ago sales stood 10.7M and 9.24M respectively for this quarter and the next, and analysts expect sales will shrink by -28.60% for the current quarter and -13.81% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 11.93% over the past 5 years.

MRSN Dividends

Mersana Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Mersana Therapeutics Inc (NASDAQ:MRSN)’s Major holders

Insiders own 11.78% of the company shares, while shares held by institutions stand at 102.08% with a share float percentage of 115.71%. Investors are also buoyed by the number of investors in a company, with Mersana Therapeutics Inc having a total of 152.0 institutions that hold shares in the company. The top two institutional holders are ECOR1 CAPITAL, LLC with over 19.36 million shares worth more than $38.92 million. As of 2024-06-30, ECOR1 CAPITAL, LLC held 15.9479% of shares outstanding.

The other major institutional holder is VR ADVISER, LLC, with the holding of over 11.33 million shares as of 2024-06-30. The firm’s total holdings are worth over $22.77 million and represent 9.3292% of shares outstanding.